Dermata Therapeutics, Inc.
corporate_fare Company Profile
Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for DRMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-17, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for DRMA spans 8-K, 10-Q, SCHEDULE 13D, 424B3.
Recent high-impact activity:
- Dermata Secures $3.4M Private Placement with Insider Backing
- Dermata Q2 Cash Drops to $4.4M, Runway Only Into Q4; Going Concern Warning Reiterated
- Dermata Posts Q2 Loss, Targets August 25 Debut for First Skincare Line
- Dermata Sets August 25 Launch for First Skincare Product, Tome Foundational Treatment, at $178
- CFO Kyri K. Van Hoose Discloses 9% Stake After $750K Private Placement Purchase
Financial Snapshot
Short Interest & Short Volume
3.18 days to coverFINRA reported short interest of 120,024 shares in DRMA as of the September 15, 2026 settlement, a 28.2% decrease from the prior period — about 3.2 days to cover at its recent average daily volume. On October 2, 2026, 28.5% of DRMA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DRMA, detected from its recent SEC filings · based on capital-structure filings through 2026-05-29.
Universal Shelf Offering Finalized · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →